Trump Signs Executive Order to Fast-Track Psychedelic Drug Approvals for Mental Health

President Donald Trump officially signed an Executive Order to accelerate research and regulatory approvals for psychedelic-based medications targeting mental illnesses. In a significant update, NRx Pharmaceuticals received a positive Discipline Review Letter from the FDA Office of Generic Drugs regarding its preservative-free ketamine program. Furthermore, FDA leadership voiced support for the potential approval of NRx's Abbreviated New Drug Application within the current review cycle. Other industry players, including GH Research and NetraMark, have welcomed the executive action for providing clearer regulatory pathways for ibogaine and depression treatments. Helus Pharma (HELP) also reaffirmed its commitment to developing novel serotonergic agonists under the new framework. The order is expected to lower bureaucratic hurdles and R&D costs, fostering a more flexible research environment at the FDA.